Tailor-made Antibodies
and Tools for Life Science
Home|||||Technical Support

CD169 antibody mouse specific - HS-495 017

CD169 is a transmembrane protein receptor expressed on macrophages
Rat monoclonal purified IgG
Cat. No.: HS-495 017
Amount: 100 µg
Price: $415.00
Cat. No. HS-495 017 100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: not recommended
IP: not tested yet
ICC: not tested yet
IHC: 1 : 500 (see remarks) gallery  
IHC-P: 1 : 100 gallery  
Clone SY-355A9
Subtype IgG2b (κ light chain)
Immunogen Synthetic peptide corresponding to residues near the carboxy terminus of mouse CD169 (UniProt Id: Q62230)
Reactivity Reacts with: mouse (Q62230).
No signal: human, rat.
Other species not tested yet.
Remarks

IHC: The antibody shows a slight synaptic background staining in the mouse brain.

Data sheet hs-495_017.pdf
Important information
This product belongs to the HistoSure product line of antibodies developed for and extensively tested in FFPE tissues.
For more information please visit our HistoSure brand website.
Cat. No.: HS-495 017
Amount: 100 µg
Price: $415.00
Background

CD169, also known as Siglec-1 or sialoadhesin, is a cell surface receptor that is most frequently expressed by certain macrophage subsets in lymphoid tissue: the marginal metallophilic macrophages (MMMs) of the spleen and the macrophages in the subcapsular sinus and medulla of lymph nodes (1). To a lesser extent, CD169 is also found on macrophages in liver, lung and colon. CD169+ macrophages are involved in immunological tolerance, antigen presentation and defense against infectious agents such as viruses (2) and play a tumor-suppressive role in malignant tumors (3). In the intact brain, CD169 stains subpopulations of macrophages in the choroid plexus, leptomeninges and circumventricular organs (4). CD169 is regulated by contact with plasma proteins, and damage to the blood-brain barrier leads to the expression of CD169 on microglia and macrophages within the parenchyma (4).